116 Chapter 4 20. Tulasne D, Deheuninck J, Lourenco FC, Lamballe F, Ji Z, Leroy C, et al. Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol Cell Biol 2004;24:10328-39. 21. Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 2006;12:4154-62. 22. Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V, et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 2009;20:2495-507. 23. Chalupsky K, Kanchev I, Zbodakova O, Buryova H, Jirouskova M, Korinek V, et al. ADAM10/17-dependent release of soluble c-Met correlates with hepatocellular damage. Folia Biol (Praha) 2013;59:76-86. 24. Xu Q, Wang C, Li B, Kim K, Li J, Mao M, et al. The impact of age on oral squamous cell carcinoma: A longitudinal cohort study of 2,782 patients. Oral Dis 2019;25:730-41. 25. Ancot F, Leroy C, Muharram G, Lefebvre J, Vicogne J, Lemiere A, et al. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. Traffic 2012;13:1261-72. 26. Clark P. Protease-mediated ectodomain shedding. Thorax 2014;69:682-4. 27. Merlin S, Pietronave S, Locarno D, Valente G, Follenzi A, Prat M. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. Cancer Sci 2009;100:633-8. 28. Gruver AM, Liu L, Vaillancourt P, Yan SC, Cook JD, Roseberry Baker JA, et al. Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET). Histopathology 2014;65:879-96. 29. Federa. https://www.federa.org/codes-conduct. 2018. Accessed: November 4 2020. 30. Khan SA, Tyagi M, Sharma AK, Barreto SG, Sirohi B, Ramadwar M, et al. Cell-type specificity of beta-actin expression and its clinicopathological correlation in gastric adenocarcinoma. World J Gastroenterol 2014;20:12202-11. 31. Li L, Yan Y, Xu H, Qu T, Wang B. Selection of reference genes for gene expression studies in ultraviolet B-irradiated human skin fibroblasts using quantitative real-time PCR. BMC Mol Biol 2011;12:8. 32. Krasnov GS, Kudryavtseva AV, Snezhkina AV, Lakunina VA, Beniaminov AD, Melnikova NV, et al. Pan-Cancer Analysis of TCGA Data Revealed Promising Reference Genes for qPCR Normalization. Front Genet 2019;10:97. 33. Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, et al. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer 2012;107:947-55. 34. Li L, Sun Z, Huang X, Li X, Sun L, Zhang L, et al. Role of c-Met expression on prognosis of head and neck cancer: A literature review and meta-analysis. Head Neck 2019;41:1999-2006. 35. Ding D, Stokes W, Eguchi M, Hararah M, Sumner W, Amini A, et al. Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer. JAMA Otolaryngol Head Neck Surg 2019;145:53-61. 36. Mermod M, Tolstonog G, Simon C, Monnier Y. Extracapsular spread in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol 2016;62:60-71. 37. Saggi S, Badran KW, Han AY, Kuan EC, St John MA. Clinicopathologic Characteristics and Survival Outcomes in Floor of Mouth Squamous Cell Carcinoma: A Population-Based Study. Otolaryngol Head Neck Surg 2018;159:51-8. 38. Saftig P, Reiss K. The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol 2011;90:527-35. 39. Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilico C, Petronzelli F, et al. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. Mol Oncol 2015;9:1760-72.
RkJQdWJsaXNoZXIy MTk4NDMw